A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy
H9X-MC-GBGJ - ClinicalTrials.gov - NCT02973100
The purpose of this study is to evaluate the efficacy and safety of investigational doses of dulaglutide in participants with type 2 diabetes on metformin monotherapy.
Trial Summary
Age Range
≥18 yearsConditions the trial is for
Type 2 DiabetesWhat the trial is testing?
DulaglutideCould I receive a Placebo?
YesEnrollment Goal
318Trial Dates
Dec 1, 2016 - Aug 14, 2017How long will I be in the trial?
Your participation could last up to 22 weeks and include 13 visits to the study center.Trial Phase
IILilly Trial Alerts
Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.
You will complete the questionnaire on another website.YesNo